Reuters
17 Nov 2026, 12:18 UTC · 50m ago
Sellas' cancer vaccine extends survival in blood cancer trial
Impact · against what's priced in
Sellas Life Sciences (SLS) receives a positive catalyst as its cancer vaccine demonstrates survival extension in a blood cancer trial. This clinical progress provides fundamental support for the stock's valuation.
- SLS+0.60
No priced-in read yet
- In context
The demonstration of extended survival in a blood cancer trial provides concrete clinical validation for the company's vaccine candidate.
Read from the article alone
- Actual

Top 1 mover · tap to explore




